☀️ JOIN SPN MOBILE
Forums
New posts
Guru Granth Sahib
Composition, Arrangement & Layout
ਜਪੁ | Jup
ਸੋ ਦਰੁ | So Dar
ਸੋਹਿਲਾ | Sohilaa
ਰਾਗੁ ਸਿਰੀਰਾਗੁ | Raag Siree-Raag
Gurbani (14-53)
Ashtpadiyan (53-71)
Gurbani (71-74)
Pahre (74-78)
Chhant (78-81)
Vanjara (81-82)
Vaar Siri Raag (83-91)
Bhagat Bani (91-93)
ਰਾਗੁ ਮਾਝ | Raag Maajh
Gurbani (94-109)
Ashtpadi (109)
Ashtpadiyan (110-129)
Ashtpadi (129-130)
Ashtpadiyan (130-133)
Bara Maha (133-136)
Din Raen (136-137)
Vaar Maajh Ki (137-150)
ਰਾਗੁ ਗਉੜੀ | Raag Gauree
Gurbani (151-185)
Quartets/Couplets (185-220)
Ashtpadiyan (220-234)
Karhalei (234-235)
Ashtpadiyan (235-242)
Chhant (242-249)
Baavan Akhari (250-262)
Sukhmani (262-296)
Thittee (296-300)
Gauree kii Vaar (300-323)
Gurbani (323-330)
Ashtpadiyan (330-340)
Baavan Akhari (340-343)
Thintteen (343-344)
Vaar Kabir (344-345)
Bhagat Bani (345-346)
ਰਾਗੁ ਆਸਾ | Raag Aasaa
Gurbani (347-348)
Chaupaday (348-364)
Panchpadde (364-365)
Kaafee (365-409)
Aasaavaree (409-411)
Ashtpadiyan (411-432)
Patee (432-435)
Chhant (435-462)
Vaar Aasaa (462-475)
Bhagat Bani (475-488)
ਰਾਗੁ ਗੂਜਰੀ | Raag Goojaree
Gurbani (489-503)
Ashtpadiyan (503-508)
Vaar Gujari (508-517)
Vaar Gujari (517-526)
ਰਾਗੁ ਦੇਵਗੰਧਾਰੀ | Raag Dayv-Gandhaaree
Gurbani (527-536)
ਰਾਗੁ ਬਿਹਾਗੜਾ | Raag Bihaagraa
Gurbani (537-556)
Chhant (538-548)
Vaar Bihaagraa (548-556)
ਰਾਗੁ ਵਡਹੰਸ | Raag Wadhans
Gurbani (557-564)
Ashtpadiyan (564-565)
Chhant (565-575)
Ghoriaan (575-578)
Alaahaniiaa (578-582)
Vaar Wadhans (582-594)
ਰਾਗੁ ਸੋਰਠਿ | Raag Sorath
Gurbani (595-634)
Asatpadhiya (634-642)
Vaar Sorath (642-659)
ਰਾਗੁ ਧਨਾਸਰੀ | Raag Dhanasaree
Gurbani (660-685)
Astpadhiya (685-687)
Chhant (687-691)
Bhagat Bani (691-695)
ਰਾਗੁ ਜੈਤਸਰੀ | Raag Jaitsree
Gurbani (696-703)
Chhant (703-705)
Vaar Jaitsaree (705-710)
Bhagat Bani (710)
ਰਾਗੁ ਟੋਡੀ | Raag Todee
ਰਾਗੁ ਬੈਰਾੜੀ | Raag Bairaaree
ਰਾਗੁ ਤਿਲੰਗ | Raag Tilang
Gurbani (721-727)
Bhagat Bani (727)
ਰਾਗੁ ਸੂਹੀ | Raag Suhi
Gurbani (728-750)
Ashtpadiyan (750-761)
Kaafee (761-762)
Suchajee (762)
Gunvantee (763)
Chhant (763-785)
Vaar Soohee (785-792)
Bhagat Bani (792-794)
ਰਾਗੁ ਬਿਲਾਵਲੁ | Raag Bilaaval
Gurbani (795-831)
Ashtpadiyan (831-838)
Thitteen (838-840)
Vaar Sat (841-843)
Chhant (843-848)
Vaar Bilaaval (849-855)
Bhagat Bani (855-858)
ਰਾਗੁ ਗੋਂਡ | Raag Gond
Gurbani (859-869)
Ashtpadiyan (869)
Bhagat Bani (870-875)
ਰਾਗੁ ਰਾਮਕਲੀ | Raag Ramkalee
Ashtpadiyan (902-916)
Gurbani (876-902)
Anand (917-922)
Sadd (923-924)
Chhant (924-929)
Dakhnee (929-938)
Sidh Gosat (938-946)
Vaar Ramkalee (947-968)
ਰਾਗੁ ਨਟ ਨਾਰਾਇਨ | Raag Nat Narayan
Gurbani (975-980)
Ashtpadiyan (980-983)
ਰਾਗੁ ਮਾਲੀ ਗਉੜਾ | Raag Maalee Gauraa
Gurbani (984-988)
Bhagat Bani (988)
ਰਾਗੁ ਮਾਰੂ | Raag Maaroo
Gurbani (889-1008)
Ashtpadiyan (1008-1014)
Kaafee (1014-1016)
Ashtpadiyan (1016-1019)
Anjulian (1019-1020)
Solhe (1020-1033)
Dakhni (1033-1043)
ਰਾਗੁ ਤੁਖਾਰੀ | Raag Tukhaari
Bara Maha (1107-1110)
Chhant (1110-1117)
ਰਾਗੁ ਕੇਦਾਰਾ | Raag Kedara
Gurbani (1118-1123)
Bhagat Bani (1123-1124)
ਰਾਗੁ ਭੈਰਉ | Raag Bhairo
Gurbani (1125-1152)
Partaal (1153)
Ashtpadiyan (1153-1167)
ਰਾਗੁ ਬਸੰਤੁ | Raag Basant
Gurbani (1168-1187)
Ashtpadiyan (1187-1193)
Vaar Basant (1193-1196)
ਰਾਗੁ ਸਾਰਗ | Raag Saarag
Gurbani (1197-1200)
Partaal (1200-1231)
Ashtpadiyan (1232-1236)
Chhant (1236-1237)
Vaar Saarang (1237-1253)
ਰਾਗੁ ਮਲਾਰ | Raag Malaar
Gurbani (1254-1293)
Partaal (1265-1273)
Ashtpadiyan (1273-1278)
Chhant (1278)
Vaar Malaar (1278-91)
Bhagat Bani (1292-93)
ਰਾਗੁ ਕਾਨੜਾ | Raag Kaanraa
Gurbani (1294-96)
Partaal (1296-1318)
Ashtpadiyan (1308-1312)
Chhant (1312)
Vaar Kaanraa
Bhagat Bani (1318)
ਰਾਗੁ ਕਲਿਆਨ | Raag Kalyaan
Gurbani (1319-23)
Ashtpadiyan (1323-26)
ਰਾਗੁ ਪ੍ਰਭਾਤੀ | Raag Prabhaatee
Gurbani (1327-1341)
Ashtpadiyan (1342-51)
ਰਾਗੁ ਜੈਜਾਵੰਤੀ | Raag Jaijaiwanti
Gurbani (1352-53)
Salok | Gatha | Phunahe | Chaubole | Swayiye
Sehskritee Mahala 1
Sehskritee Mahala 5
Gaathaa Mahala 5
Phunhay Mahala 5
Chaubolae Mahala 5
Shaloks Bhagat Kabir
Shaloks Sheikh Farid
Swaiyyae Mahala 5
Swaiyyae in Praise of Gurus
Shaloks in Addition To Vaars
Shalok Ninth Mehl
Mundavanee Mehl 5
ਰਾਗ ਮਾਲਾ, Raag Maalaa
What's new
New posts
New media
New media comments
New resources
Latest activity
Videos
New media
New comments
Library
Latest reviews
Donate
Log in
Register
What's new
New posts
Menu
Log in
Register
Install the app
Install
Welcome to all New Sikh Philosophy Network Forums!
Explore Sikh Sikhi Sikhism...
Sign up
Log in
Discussions
Hard Talk
Govt Says Unfair To Blame India On Alarm Over 'New Delhi' Bug
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="spnadmin" data-source="post: 131499" data-attributes="member: 35"><p>The problem of drug resistant bacterial infections has become a worldwide problem. A report from Pakistan.</p><p></p><p> <strong>Reducing antibiotics not enough to stem resistance</strong></p><p></p><p> Zulfiqar A Bhutta and Syed Rehan Ali</p><p> </p><p> 26 March 2008 | | </p><p></p><p><img src="http://www.scidev.net/scidev_images/CDC_pneumonia_x_ray.jpg" alt="" class="fr-fic fr-dii fr-draggable " style="" /> Xray of lungs infected by pneumonia</p><p> CDC</p><p> </p><p> <strong>Reducing antibiotic use is not enough to curb the rise of resistance in the developing world, say <em>Zulfiqar A. Bhutta</em> and <em>Syed Rehan Ali</em></strong>.</p><p></p><p> Ever since the advent of antibiotics, the phenomenon of increasing resistance to commonly used antibiotics has been well-recognised. </p><p></p><p> Excessive and uncontrolled use of antibiotics in humans and animals are major contributors to the spread of resistance. In a rapidly globalising world where people have easy access to long-distance travel, antibiotic-resistant organisms can easily cross continents and infect individuals.</p><p></p><p><span style="color: Red"> Resistance can also be transferred between different disease-causing bacteria, with deadly consequences for health systems in both developed and developing countries.</span></p><p></p><p> While the extent of resistance and its health and economic costs are well-documented in developed countries, relatively little is known about the burden and consequences of resistance in developing countries, where data are sp{censored} and monitoring systems poor. </p><p></p><p>Nevertheless, given that many developing countries have enormously high rates of infectious disease, the directly attributable economic costs of resistance must be considerable. <span style="color: Red">Lack of access to effective treatment for resistant infections is an important additional contributor to morbidity. </span></p><p><span style="color: Red"></span></p><p></p><p> <strong>Poverty and inequity</strong></p><p></p><p><span style="color: Red"> Poverty and inequity are major drivers of antimicrobial resistance. In developing countries they are linked to inadequate access to effective drugs, unregulated dispensing by unqualified staff and truncated therapy for reasons of cost.</span></p><p> </p><p> In addition, substandard generics — and counterfeit medications — are burgeoning because of the cost of branded antibiotics. <span style="color: Red">Poor people often buy them from uncontrolled street vendors and even then cannot afford to complete a full course of treatment.</span></p><p></p><p> This vicious cycle promotes the emergence of antimicrobial resistance and can make treatment less effective.</p><p></p><p> The widespread and frequently unnecessary use of antibiotics is also related to health system weaknesses, with poorly trained care providers and lack of suitable laboratory facilities frequently resulting in inappropriate treatment. </p><p></p><p> For example, because of limited capacity to obtain a bacteriological diagnosis of typhoid fever, treatment is often initiated with ineffective antibiotics and changed to second line therapy following clinical treatment failure. In other instances, physicians may choose to initiate treatment unnecessarily with second line antibiotics. Sometimes alternative antibiotics may not be available at all. </p><p></p><p> <strong> Extra costs </strong></p><p></p><p><span style="color: Red"> As a result of widespread resistance among common bacterial pathogens such as <em>Streptococcus pneumoniae</em> and <em>Hemophilus influenzae</em> that cause childhood pneumonia, it is no longer feasible to treat cases of moderate-to-severe pneumonia with first line antibiotics like co-trimoxazole. Although health systems are gearing to change to amoxicillin for the treatment of childhood pneumonia, this will take time and considerable resources.</span></p><p></p><p> Resistant bacteria are often more virulent, leading to more severe illness. Multidrug-resistant (MDR) typhoid, for example, is associated with greater clinical severity of illness and more complications than the non-resistant form of the disease. </p><p></p><p> One study showed that despite treatment with injectable ceftriaxone, the mean time before children with MDR typhoid lost their fever was 7.2 days, compared with 6.3 days for sensitive typhoid. The drug treatment costs for an episode of MDR typhoid fever, a common childhood infection, are considerably higher than for sensitive typhoid. So increasing antibiotic resistance is associated with higher economic burden on health systems from the combination of higher rates of complications and enhanced health care costs.</p><p></p><p> This extra economic burden can be considerable. Our findings from population-based studies on typhoid fever in urban Karachi indicate that the average cost of illness was more than US$50 per episode, most of which was out-of-pocket costs for antibiotics. </p><p></p><p> <strong> Pragmatic action</strong></p><p></p><p> Rational drug use is a cornerstone for reducing inappropriate antimicrobial use and requires physician and patient education as well as industry collaboration. In addition, given widespread over-the-counter availability of antibiotics in many developing countries, regulation and oversight of antibiotic use are key interventions. </p><p></p><p> In addition, every effort needs to be made to “protect” newer and second line antibiotics from widespread use in health facilities or general practice. Merely reducing antibiotic use may be simplistic. But selective and appropriate use of antibiotics (with the correct dose and duration of therapy) may make a difference. </p><p></p><p> The challenge is to implement these strategies within health systems by engaging both the public and private sectors. This may require a series of measures including staff training, strengthening of health systems and rational prescribing, as well as regulation of antibiotic use and over-the-counter prescribing. </p><p></p><p> <em>Zulfiqar A Bhutta is the professor and chairman, department of paediatrics & child health, and Syed Rehan Ali is an assistant professor, both at the Aga Khan University, Karachi, Pakistan.</em></p></blockquote><p></p>
[QUOTE="spnadmin, post: 131499, member: 35"] The problem of drug resistant bacterial infections has become a worldwide problem. A report from Pakistan. [B]Reducing antibiotics not enough to stem resistance[/B] Zulfiqar A Bhutta and Syed Rehan Ali 26 March 2008 | | [IMG]http://www.scidev.net/scidev_images/CDC_pneumonia_x_ray.jpg[/IMG] Xray of lungs infected by pneumonia CDC [B]Reducing antibiotic use is not enough to curb the rise of resistance in the developing world, say [I]Zulfiqar A. Bhutta[/I] and [I]Syed Rehan Ali[/I][/B]. Ever since the advent of antibiotics, the phenomenon of increasing resistance to commonly used antibiotics has been well-recognised. Excessive and uncontrolled use of antibiotics in humans and animals are major contributors to the spread of resistance. In a rapidly globalising world where people have easy access to long-distance travel, antibiotic-resistant organisms can easily cross continents and infect individuals. [COLOR=Red] Resistance can also be transferred between different disease-causing bacteria, with deadly consequences for health systems in both developed and developing countries.[/COLOR] While the extent of resistance and its health and economic costs are well-documented in developed countries, relatively little is known about the burden and consequences of resistance in developing countries, where data are sp{censored} and monitoring systems poor. Nevertheless, given that many developing countries have enormously high rates of infectious disease, the directly attributable economic costs of resistance must be considerable. [COLOR=Red]Lack of access to effective treatment for resistant infections is an important additional contributor to morbidity. [/COLOR] [B]Poverty and inequity[/B] [COLOR=Red] Poverty and inequity are major drivers of antimicrobial resistance. In developing countries they are linked to inadequate access to effective drugs, unregulated dispensing by unqualified staff and truncated therapy for reasons of cost.[/COLOR] In addition, substandard generics — and counterfeit medications — are burgeoning because of the cost of branded antibiotics. [COLOR=Red]Poor people often buy them from uncontrolled street vendors and even then cannot afford to complete a full course of treatment.[/COLOR] This vicious cycle promotes the emergence of antimicrobial resistance and can make treatment less effective. The widespread and frequently unnecessary use of antibiotics is also related to health system weaknesses, with poorly trained care providers and lack of suitable laboratory facilities frequently resulting in inappropriate treatment. For example, because of limited capacity to obtain a bacteriological diagnosis of typhoid fever, treatment is often initiated with ineffective antibiotics and changed to second line therapy following clinical treatment failure. In other instances, physicians may choose to initiate treatment unnecessarily with second line antibiotics. Sometimes alternative antibiotics may not be available at all. [B] Extra costs [/B] [COLOR=Red] As a result of widespread resistance among common bacterial pathogens such as [I]Streptococcus pneumoniae[/I] and [I]Hemophilus influenzae[/I] that cause childhood pneumonia, it is no longer feasible to treat cases of moderate-to-severe pneumonia with first line antibiotics like co-trimoxazole. Although health systems are gearing to change to amoxicillin for the treatment of childhood pneumonia, this will take time and considerable resources.[/COLOR] Resistant bacteria are often more virulent, leading to more severe illness. Multidrug-resistant (MDR) typhoid, for example, is associated with greater clinical severity of illness and more complications than the non-resistant form of the disease. One study showed that despite treatment with injectable ceftriaxone, the mean time before children with MDR typhoid lost their fever was 7.2 days, compared with 6.3 days for sensitive typhoid. The drug treatment costs for an episode of MDR typhoid fever, a common childhood infection, are considerably higher than for sensitive typhoid. So increasing antibiotic resistance is associated with higher economic burden on health systems from the combination of higher rates of complications and enhanced health care costs. This extra economic burden can be considerable. Our findings from population-based studies on typhoid fever in urban Karachi indicate that the average cost of illness was more than US$50 per episode, most of which was out-of-pocket costs for antibiotics. [B] Pragmatic action[/B] Rational drug use is a cornerstone for reducing inappropriate antimicrobial use and requires physician and patient education as well as industry collaboration. In addition, given widespread over-the-counter availability of antibiotics in many developing countries, regulation and oversight of antibiotic use are key interventions. In addition, every effort needs to be made to “protect” newer and second line antibiotics from widespread use in health facilities or general practice. Merely reducing antibiotic use may be simplistic. But selective and appropriate use of antibiotics (with the correct dose and duration of therapy) may make a difference. The challenge is to implement these strategies within health systems by engaging both the public and private sectors. This may require a series of measures including staff training, strengthening of health systems and rational prescribing, as well as regulation of antibiotic use and over-the-counter prescribing. [I]Zulfiqar A Bhutta is the professor and chairman, department of paediatrics & child health, and Syed Rehan Ali is an assistant professor, both at the Aga Khan University, Karachi, Pakistan.[/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Discussions
Hard Talk
Govt Says Unfair To Blame India On Alarm Over 'New Delhi' Bug
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top